Silhouette Francaise Medical Limited, the professional manufacturer and global supplier of the renowned BELLA brand of medical aesthetic injectables and skin regeneration solutions, has officially announced the upcoming introduction of a new standardized anti-counterfeit security label. This significant development, which will take effect beginning September 1, 2026, underscores BELLA's unwavering commitment to protecting its brand integrity, combating counterfeit products, and ensuring that medical professionals and patients worldwide receive only authentic, high-quality aesthetic solutions.
In an official statement dated August 17, 2026, BELLA provided important clarifications regarding product authentication and packaging identification. The company confirmed that all BELLA products previously exported by Silhouette Francaise Medical Limited did not carry any official adhesive anti-counterfeit label. While some earlier packaging may have contained printed QR codes, BELLA emphasized that these printed codes should not be confused with or mistaken for the new adhesive anti-counterfeit labels that are now being introduced as part of the company's enhanced security framework.
One of the most critical points addressed in the official statement concerns the interpretation of product authenticity. BELLA made it explicitly clear that the absence of an adhesive anti-counterfeit label on previously distributed products does not mean that a BELLA product is counterfeit. All genuine products previously supplied by the company remain fully authentic and may continue to be sold, distributed, and used within their applicable shelf life. This clarification provides essential reassurance to distributors, importers, and medical practitioners who currently hold inventory that was manufactured and shipped prior to the implementation of the new labeling system.
Additionally, BELLA strongly cautioned against unauthorized third-party labeling practices. The statement clarified that any adhesive security label or identification sticker independently applied by a distributor, importer, or other third party does not represent BELLA's official authentication system. No external party is authorized to claim that only products carrying its own label are genuine, nor to suggest that BELLA products without such third-party labels are counterfeit. Such claims and statements do not represent BELLA's official position in any capacity, and the company urges all stakeholders to disregard unofficial authentication methods.
The introduction of the new standardized official adhesive anti-counterfeit label represents a strategic initiative designed to protect the BELLA trademark, effectively combat counterfeit products in the global marketplace, and significantly improve product traceability throughout the supply chain. By implementing this unified and standardized security measure across all newly manufactured and packaged BELLA products, the company aims to create a more transparent, secure, and trustworthy distribution network for its extensive global customer base.
Medical professionals, clinic owners, distributors, and end-users across Europe, the Middle East, Latin America, and Asia are strongly encouraged to stay informed through BELLA's official communication channels. To ensure product authenticity, stakeholders should rely exclusively on official announcements published directly by BELLA rather than unofficial claims from third parties. This proactive and transparent approach to brand protection further reinforces BELLA's dedication to maintaining the highest standards of safety, consistency, and clinical excellence that healthcare professionals around the world have trusted for years.
